IL6 and myeloid sarcoma: The results presented here suggest that similar to NMOSD and MOGAD, IL-6 may play a role in MS, emphasizing the relevance of IL-6 as a biomarker of disease severity and as a potentially critical player in disease pathogenesis and progression.